CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

Introduction/Background

What Is GLP-1?[a-c]

GLP-1: Multiple Direct Effects on Human Physiology[a,b]

GLP-1 RAs and Experimental Models of CVD

GLP-1 RAs and BP Reduction

GLP-1 RAs and Lipids Reduction

GLP-1 RA: Approved or in Development

SAVOR-TIMI, EXAMINE, TECOS: Topline Results[a-d]

Differences Between the 2 Classes of Incretin Agent

EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

EMPA-REG Microvascular Outcomes: Renal Protection

LEADER: Primary Outcome*

LEADER: CV Death

LEADER: Time to First Renal Event -- Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death

Potential Mechanisms for CV Benefit Associated With Empagliflozin

ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

SUSTAIN-6 (Semaglutide): Primary Outcome Results

Short-Acting GLP-1 RAs vs Long-Acting GLP-1 RAs

CDA Treatment Guidelines: 2016 Interim Update SGLT2 Inhibition

Conclusions

Abbreviations

Abbreviations (cont)